We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
A recently published decision of the Commissioner of Patents in Re Immunex Corporation Patent Application No. 583,988 has provided prospective Canadian patentees of inventions relating to monoclonal antibodies with some long-sought clarity in this rapidly evolving practice area
